
Zhejiang Taimei Medical Technology Co., Ltd.
2576.HKHKSETechnologySoftware - Application
最新資料
HK$5.50
−HK$0.045 · -0.81%
2576.HK公司概覽
盤中時間採用HKT。市場資料可能有所延遲。
公司概況
公司網站Zhejiang Taimei Medical Technology Co., Ltd., established in 2013 and based in Jiaxing, China, specializes in delivering sophisticated digital operational platforms specifically designed for the biopharmaceutical industry across the country. The company's core offering is TrialOS, a comprehensive digital collaboration platform that seamlessly integrates all participants throughout the drug development and research lifecycle. This ecosystem effectively links hospitals, pharmaceutical firms, external service providers, regulatory bodies, and patients, among other key industry stakeholders. Its extensive portfolio of software solutions caters to various critical aspects of clinical research and drug development. For streamlining clinical trial operations, Taimei Medical provides tools like eCooperate, which optimizes management systems and leverages big data for informed decision-making. Other related offerings include eArchives for managing master files, eCollect for electronic data capture, eCollege for training administration, eQuality for electronic audit processes, and eBalance for interactive web-based responses. Innovations such as eVisit Patient Reported Outcomes are designed to enhance patient data input and accuracy, while eTime supports project time management, and eImage facilitates medical image interpretation. Furthermore, the company supplies specialized software tailored for hospitals and Good Clinical Practice (GCP) sites. These include eTrial for managing Phase I wards, eSite and NomenCTMS for comprehensive clinical trial management at study sites, and intelligent platforms like GCP-X and Intelligent Investigator. Solutions such as eScreening assist with subject information management and deduplication, while IIT-EDC and the Investigator-Initiated Clinical Trial Management System support investigator-initiated studies and their associated data management. In the crucial domain of drug safety, the company offers robust pharmacovigilance software solutions. This includes both global and intelligent eSafety systems, alongside the SAE Manager for efficient communication and management of critical safety data during clinical trials. Complementing these, Zhejiang Taimei also develops marketing software and a variety of other digital innovation solutions.
- 產業
- Software - Application
- 部門
- Technology
- 總部
- CN
- 執行長
- Wan Yunyun
- 上市以來
- 2024年10月8日
- 僱員
- 681
市場位置
日內區間
目前HK$5.50,
52週區間
目前HK$5.50,
- 開盤價
- HK$5.60
- 前收盤價
- HK$5.545
- 成交量
- 55.58萬
- 0.68× 平均值
- 平均成交量
- 81.24萬
- 日均成交量
- 市值
- 31.01億 HKD
- 貝塔
- 0.01
- 市場參考 1
- 50天平均值
- HK$5.8397
- 低於平均水平-5.82%
- 200天平均值
- HK$4.7971
- 高於平均水平+14.65%
財務數據
財務快照
最近十二個月估值與收益率
- 企業價值
- 14.41億 CNY
- EV/EBITDA
- -49.5×
- 盈餘收益率
- -2.08%
- 自由現金流收益率
- -2.15%
獲利能力和效率
- 股東權益報酬率
- -3.72%
- 資產報酬率
- -2.68%
- 投入資本報酬率
- -4.78%
財務健康
- 流動比率
- 4.47×
財務報表
利潤率趨勢
獲利能力占已公布營收的百分比。
損益趨勢
營收
營業利益
淨利
| 項目(CNY) | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 4.99億 CNY | 5.51億 CNY | 5.73億 CNY | 5.49億 CNY | 4.66億 CNY |
| 銷貨成本 | 2.87億 CNY | 3.26億 CNY | 3.94億 CNY | 3.64億 CNY | 3.02億 CNY |
| 毛利 | 2.12億 CNY | 2.25億 CNY | 1.79億 CNY | 1.85億 CNY | 1.64億 CNY |
| 研究與開發 | 7663.39萬 CNY | 8705.4萬 CNY | 1.69億 CNY | 2.34億 CNY | 2.25億 CNY |
| 銷售、一般及管理費用 | 1.97億 CNY | 3.82億 CNY | 3.85億 CNY | 4898.8萬 CNY | 4621.9萬 CNY |
| 營業費用 | 2.73億 CNY | 4.77億 CNY | 5.76億 CNY | 6.28億 CNY | 6.7億 CNY |
| 利息收入 | 3472.25萬 CNY | 3577.4萬 CNY | 4165.4萬 CNY | 2288.4萬 CNY | 2873.8萬 CNY |
| 利息支出 | 81.14萬 CNY | 72.7萬 CNY | 143.1萬 CNY | 268.1萬 CNY | 270.9萬 CNY |
| 折舊和攤銷 | 1946.48萬 CNY | 3994.6萬 CNY | 5196.2萬 CNY | 5552.5萬 CNY | 3650.6萬 CNY |
| 營業利益 | −6150萬 CNY | −2.52億 CNY | −3.97億 CNY | −4.43億 CNY | −5.06億 CNY |
| 淨利 | −4173.71萬 CNY | −2.15億 CNY | −3.47億 CNY | −4.13億 CNY | −4.8億 CNY |
公司資料更新於 2026年8月24日。
2576.HK同業公司
繼續GoAI的研究
在 GoAI 中研究2576.HKresearch.disclaimer





